Join
Live feed
·
PRReleasevia Quantisnow
Medicenna Therapeutics Corp. logo

Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

ByQuantisnow·Wall Street's wire, on your screen.
MDNA· Medicenna Therapeutics Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MDNA (Medicenna Therapeutics Corp.) and more on Quantisnow.